CEO of drugmaker GSK to step down by year's end
Dame Emma Walmsley, CEO of GSK arrives for a business roundtable attended by President Donald Trump and Britain's Prime Minister Keir Starmer at Chequers near Aylesbury, England, Thursday, Sept. 18, 2025. Credit: AP/Evan Vucci
LONDON — GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down Dec. 31 after more than eight years at the head of the London-based drugmaker.
Walmsley, 56, will be replaced by Luke Miels, currently GSK’s chief commercial officer, the company said in a statement released on Monday.
While GSK achieved a number of strategic successes under Walmsley, including the spinoff of the consumer health care business Haleon, it has disappointed investors. GSK’s shares rose 3.3% to 1534.50 pence in early trading, making it the biggest gainer on the London Stock Exchange.
GSK’s shares fell 11% between April 1, 2017, when Walmsley became CEO, and last Friday.
“Despite the progress, the share price performance has been lackluster,” Derren Nathan, head of equity research at U.K.-based Hargreaves Lansdown,” said in a note to investors.
“Although her record of delivering on financial guidance has been strong, the company’s growth rates remain stuck in single-digit territory.”
'Tis the season for the NewsdayTV Holiday Show! The NewsdayTV team looks at the most wonderful time of the year and the traditions that make it special on LI.
'Tis the season for the NewsdayTV Holiday Show! The NewsdayTV team looks at the most wonderful time of the year and the traditions that make it special on LI.
